Cargando…
Grapiprant: A snapshot of the current knowledge
Grapiprant is the pioneer member of the novel piprant class, a potent and specific antagonist of the prostaglandin E2 receptor 4. It has been approved in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by t...
Autores principales: | Sartini, Irene, Giorgi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518515/ https://www.ncbi.nlm.nih.gov/pubmed/34057218 http://dx.doi.org/10.1111/jvp.12983 |
Ejemplares similares
-
Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation
por: Kirkby Shaw, Kristin, et al.
Publicado: (2015) -
Quantification of Grapiprant and Its Stability Testing under Changing Environmental Conditions
por: Gumułka, Paweł, et al.
Publicado: (2022) -
Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs
por: de Salazar Alcalá, Andrea García, et al.
Publicado: (2019) -
Correction to: Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs
por: de Salazar Alcalá, Andrea García, et al.
Publicado: (2019) -
The Novel Coronavirus – A Snapshot of Current Knowledge
por: Brüssow, Harald
Publicado: (2020)